AUTHOR=Saleem Muhammad Rizwan , Khan Muhammad Talha 

TITLE=Teplizumab: a promising intervention for delaying type 1 diabetes progression

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 16 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1533748

DOI=10.3389/fendo.2025.1533748

ISSN=1664-2392

ABSTRACT=Type 1 diabetes (T1D) arises from an autoimmune attack on pancreatic beta cells, leading to a reliance on external insulin to maintain glucose levels. In recent years, research has increasingly focused on preventive strategies for individuals at high risk. A promising new intervention in this field is Teplizumab, the first approved disease-modifying therapy for T1D. Teplizumab is designed to delay progression to stage 3 T1D in adults and children aged 8 years and older who are diagnosed with stage 2 T1D.